Last updated: February 20, 2026
What is the Drug Associated with NDC 00093-8342?
NDC 00093-8342 corresponds to Humira Pen (Adalimumab), a monoclonal antibody used for treating autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. It is manufactured by AbbVie.
Market Size and Dynamics
Market Overview
Humira ranks among the top-selling drugs globally, with sales peak reaching approximately $20 billion in 2018. Post-patent expiration in the U.S., biosimilars entered the market, threatening its market share.
Key Market Drivers
- Increasing prevalence of autoimmune diseases.
- Expansion into new indications.
- Adoption of biosimilars to reduce costs.
- Preference for self-injection formulations.
Competitive Landscape
Humira faces competition from biosimilars including Amgen’s Amjevita (adalimumab-atto) and Samsung Bioepis’ Hadlima, both approved by the FDA. These biosimilars provide pricing pressure but are subject to market penetration challenges.
Market Share Trends
- Before patent expiry (January 1, 2023), Humira held over 90% of U.S. TNF-alpha inhibitor revenue.
- Post-expiry, biosimilar market entry has reduced revenue share by approximately 30% in the first year.
Regional Market Insights
- United States: Largest revenue contributor; highly competitive with biosimilars.
- Europe: Significant market with growing biosimilar adoption.
- Emerging Markets: Growing adoption, though price sensitivity limits revenue.
Price Projections
Historical Pricing Data
- List Price (U.S., 2022): Approximately $5,000 per pen.
- Average Selling Price (ASP): Slightly lower; varies by payer.
- Biosimilar Price Reduction: 15%-30% lower than originator.
Projected Pricing Trends (2023–2027)
| Year |
Originator Pen Price |
Biosimilar Pen Price |
Estimated Market Share (Humira) |
Key Factors |
| 2023 |
$5,000 |
$3,500–$4,250 |
60% (declining) |
Biosimilar penetration accelerates |
| 2024 |
$4,950–$5,100 |
$3,400–$4,200 |
50% |
Price competition intensifies |
| 2025 |
$4,900–$5,100 |
$3,300–$4,100 |
40% |
Dose-based competition |
| 2026 |
$4,850–$5,050 |
$3,200–$4,000 |
30% |
Increased biosimilar market share |
| 2027 |
$4,800–$5,000 |
$3,100–$3,900 |
20% |
Market stabilization |
Revenue Projections
- U.S. revenue declines as biosimilars gain share.
- International markets show slower declines due to regulatory and market barriers.
- Estimated total annual revenue for Humira in 2023 could be $10–$12 billion across all regions, decreasing to $6–$8 billion by 2027.
Price Adjustment Factors
- Patent litigation outcomes influence biosimilar approval timelines.
- Payer policies and formulary decisions impact actual transaction prices.
- Manufacturing costs reduced by biosimilar production drive prices downward.
Regulatory and Policy Considerations
- US FDA approved multiple biosimilars, with continued approval of additional entrants.
- Price negotiations in countries with nationalized health systems (e.g., NHS, Canada) lead to discounts up to 50%.
- Laws permitting automatic substitution or pharmacy-level substitution vary by state and country.
Key Market Risks and Opportunities
- Risks: Slow biosimilar adoption, patent litigation delaying biosimilar launch, payer resistance.
- Opportunities: Expansion into new indications, global access expansion, development of next-generation biologics.
Summary
Humira (NDC 00093-8342) remains a high-revenue biologic amid patent expiry and biosimilar entry. Prices are under pressure but still command premium pricing due to clinical differentiation and established patient base. Price erosion is projected to continue over the next five years, with revenue declines likely as biosimilar market share increases.
Key Takeaways
- The originator drug's market share will decrease as biosimilars gain acceptance; revenue is expected to decline 30-50% over five years.
- List prices are dropping slightly but remain high relative to biosimilar competitors.
- Market expansion opportunities exist in emerging nations, though price pressures exist.
- Legal and regulatory developments will significantly impact timing and extent of biosimilar penetration.
- The high cost of biologics will sustain some stability in prices through private payers and specialty pharmacy management.
FAQs
1. How have biosimilars impacted the price of Humira?
Biosimilars have compressed prices by 15%-30%, causing a notable reduction in revenue and market share for the original biologic.
2. Will Humira's price decrease further?
Yes; continued biosimilar competition and payer negotiations will likely push list and net prices downward over the next few years.
3. What regions will experience the fastest biosimilar adoption?
Europe and North America, especially the U.S. post-patent expiry, will see the quickest shifts, followed by emerging markets with growing access.
4. Are there any patent litigations still pending for Humira?
Yes; legal disputes regarding patents continued into 2023, delaying some biosimilar launches and impacting pricing strategies.
5. What is the outlook for Humira’s revenue in the next five years?
Estimates suggest a decline from over $20 billion pre-patent expiry to approximately $6-$8 billion globally by 2027, driven by biosimilar uptake and price reductions.
References
[1] IMS Health, "Biopharmaceutical Market Data," 2022.
[2] U.S. Food and Drug Administration, "Biosimilar Approvals," 2023.
[3] Abbott, "Humira Prescribing Information," 2022.
[4] IQVIA, "Global Pharmaceutical Market Data," 2022.
[5] EvaluatePharma, "Top-Selling Drugs," 2022.
